Fig. 1

TROJAN was highly expressed and predicted poor survival in ER+ breast cancer. a Kaplan-Meier analysis of the relapse-free survival of 92 ER+ breast cancer patients in the FUSCC cohort. A log-rank test was used to determine the statistical significance between the low TROJAN expression group (n = 57) and the high TROJAN expression group (n = 35). b Kaplan-Meier analysis of the disease-free survival of 600 ER+ breast cancer patients in the TCGA cohort (low TROJAN expression group, n = 566; high TROJAN expression group, n = 183). c Kaplan-Meier analysis of the relapse-free survival of 762 ER+ breast cancer patients in the kmplot cohort (low TROJAN expression group, n = 561; high TROJAN expression group, n = 201). d Multivariate cox regression of clinicopathologic variables and TROJAN expression levels in the FUSCC cohort and TCGA cohort. HR, hazard ratio; CI, confidence interval. e Gene Ontology (GO) analysis of the top 250 genes correlated with TROJAN in FUSCC ER+ breast cancer patient cohort (GSE115144) and TCGA cohort. FDR, false discovery rate